Objective Although the prognosis of natalizumab-associated progressive multifocal leukoencephalopathy (PML) seems to be better than HIV-associated PML, little is known about the long-term functional outcome in multiple sclerosis (MS) patients and the subsequent return of MS disease activity. We evaluated retrospectively 15 patients with natalizumab-associated PML treated at our centre.
Patients and methods Fifteen MS-PML patients (nine women, six men) were referred to us from adjacent local centres. The patients had a median natalizumab exposure of 34 months at PML diagnosis. They received standardised treatment as described in previous work. Expanded Disability Status Scale (EDSS) and Karnofsky score in the year pre-PML, at PML-diagnosis (pre-immune reconstitution inflammatory syndrome (IRIS)) and post-PML were determined in 3–6 monthly intervals.
Results The median follow-up of these 15 patients was 21.5 months. None of the 15 patients died. Three patients had a Karnofsky score of 80 or higher, nine patients between 50–70 and three patients of 40 or lower at latest examination. Eight of the 15 patients developed seizures during acute PML phase. Fifty percent of those patients were not seizure-free one year post PML, despite continuation of antiepileptic treatment. The median EDSS in the year pre-PML was 2.5, 4.5 at PML diagnosis, 6.5 post-IRIS and 5.5 at latest examination. CSF became virus-free in eight of the 15 patients after a median time of 4.5 months. In nine patients, disease reappeared after a median time of seven months from PML diagnosis.
Conclusions Although the clinical outcome of natalizumab-treated PML patients is much better than in patients with HIV-associated PML, this may be further improved by treatment at reference centres using standardised therapy regimens and transient intensive care if needed. Systematic studies of appropriate MS immunotherapies after PML are critically needed.
- Multiple Sclerosis
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the central nervous system, which usually occurs in the setting of immunosuppression with HIV or cancer patients.1 PML was first described in 1958 in a patient with Hodgkin's disease and in two patients with chronic lymphocytic leukaemia.2 The assumption of a viral aetiology of PML was made after 1959.3 ,4 In 1965, intranuclear inclusion bodies in oligodendrocytes were identified by electron microscopy as viral material belonging to the papova group.5 The causative virus of PML was named JC virus, after the initials of the index patient John Cunningham.6
The majority of the population has been exposed to the JC virus—mostly before the age of 15,7 and about 60% to 80% of the adult humans produce persistent antibodies against JCV, which seem to be the most reliable tools to detect latent infection.8 In July 2006, the α4-integrin monoclonal antibody natalizumab (Tysabri, BiogenIdec) was reintroduced to the market as a monotherapy for first-line treatment of patients with highly active relapsing-remitting multiple sclerosis.9 Earlier, the drug had been withdrawn in February 2005 from clinical studies after first approval in 2004 by the US Food and Drug Administration because of three cases of PML in the SENTINEL study10 ,11 and in a clinical trial for Crohn's disease.12 Approximately 108 300 patients have been treated with natalizumab as of September 2012, and 331 cases of natalizumab-associated PML were reported worldwide as of February 2013, with an overall risk of 2,84 cases per 1000 patients (https://www.biogenidec.com). The incidence of PML increases with the duration of treatment. As of February 2013, 70 (22%) of the worldwide reported natalizumab-associated PML patients have died. In comparison, the one-year survival rate of HIV-associated PML cases after introduction of HAART is about 50%.13 Since the time of our very early report of the successful management of natalizumab-associated PML,14 15 patients had been referred to our care, and were subjected to standardised treatment regimens. The goal of this retrospective study was to determine whether a single-centre approach has positive impact on the outcome of these patients, and if suitable follow-up immunotherapies for treatment of multiple sclerosis (MS) can be identified.
We evaluated clinical outcome and functional disability of 15 PML patients—nine women and six men, who were referred to our clinic mostly from the Northwestern part of Germany—using Expanded Disability Status Scale (EDSS) and Karnofsky Performance Scale15 in the year pre-PML diagnosis, at PML diagnosis (pre-immune reconstitution inflammatory syndrome IRIS) and post-IRIS in 3–6 monthly intervals, with a median follow-up time of 21.5 months. Ten patients were examined and rated by SD. One patient was examined in our neuroimmunological outpatient setting by different physicians in our clinic. We received follow-up information by a local chief of neurology from one patient. The other three patients were examined and rated by IK, AC or KH. All 15 patients were reassessed by SD on the basis of clinical examinations or of oral and written information from other physicians, patients themselves or relatives. All compiled results were also scored by RH. Both neurologists are certificated EDSS-rater (C-Level) (http://www.neurostatus.net). Mild disability was defined by Karnofsky scores of 80 or higher, moderate disability by Karnofsky scores of 50–70 and severe disability by Karnofsky scores of 40 or lower. The retrospective analysis of patient data has been approved by the Bochum ethics committee 4566-13.
The cerebrospinal fluid (CSF) and serum analyses for JCV-DNA of 14 patients were performed at the Institute for Virology, University Duesseldorf, which is one of Germany's reference centres. Frozen pre-PML sera were retrieved from our own nationwide test centre for anti-natalizumab antibodies.16
For MRI, routine scans at 1.5 Tesla machines, a standard protocol for MS (T1-weighted scans with and without Gadolinium (GD) contrast, T2-weighted scans and fluid inversion recovery (FLAIR) images) were used and scans were evaluated by a single neuroradiologist (CL). We decided to perform a brain MRI control initially every 4 weeks, then in 2–3 months intervals, and in case of clinical worsening.
All 15 patients received plasma exchange (PLEX)/immunoadsorption (IA) at the point of PML diagnosis verified by CSF JCV detection to remove natalizumab and supportive treatment with mefloquine (typically with a loading dose of 250 mg for 3 days and then typically 250 mg once a week) and mirtazapine (usually a starting dose of 30 mg per day, if tolerated, a stepwise increase up to 60 mg per day was made).
The definition of IRIS requires the diagnosis of natalizumab-associated PML and paradox worsening of neurological symptoms following the removal of natalizumab by PLEX or IA. Typically, extension of lesions without contrast enhancement or mass effect on neuroimaging was considered to be due to PML progression. Early-PML-IRIS was defined by the evidence of contrast enhancement at the time of PML diagnosis. In late-PML-IRIS contrast enhancement or worsening of PML lesions were observed.17 All patients with IRIS received intravenous high-dose corticosteroids (typically 1g per 3–5 days), and in two patients, mannitol (4×125 ml/day) for treatment of cerebral oedema was administered.
Typically, prescribed anticonvulsive medication was levetiracetam 2×500 mg per day with a maximum dose of 2×1500 mg. Other antiepileptic drugs used in these patients were lamotrigine, topiramate or lacosamide to adapt antiepileptic treatment after failure of levetiracetam. During the acute phase of seizures, most patients received benzodiazepines such as lorazepam or clonazepam. Transient intensive care or intermediate care management was needed in seven of the 15 patients because of clinical deterioration mostly due to IRIS and/or in case of complex-focal/secondarily generalised seizures.
Clinical relapses post-PML were treated with high-dose methylprednisolone with a typical dose of 1g i.v. for 3–5 days. Glatiramer acetate, interferonß-1a, fingolimod or immunoglobulins were used as post-PML immunotherapy.
Patient demographics and risk factors
In the preceding years, treatment duration for more than 2 years, positive anti-JCV-antibody status and prior use of immunosuppressive agents have been independently identified as risk factors for the development of PML.18 Our 15 patients included nine women and six men aged 30–52 years (mean 39.3 years±6.2; median 39 years) at PML diagnosis and had a mean MS duration of 12.3 years. All patients were of Caucasian origin. At PML diagnosis natalizumab exposure varied from 13 to 64 months (mean 34.4 months±11.4); median 34 months) respectively from 14 to 62 infusions (mean 34.3 infusions±11.1; median 32 infusions). All patients had previous immunomodulatory therapy (14 interferons, 1 glatiramer acetate). Six of these received more than one immunomodulatory therapy and two (13.3%) received immunosuppressive drugs (1 mitoxantrone, 1 azathioprine) (table 1).
Retrospective analysis of frozen and stored pre-PML serum samples showed a positive anti-JCV antibody status in all eight of the 15 patients where samples were available; in seven patients, no pre-PML serum was stored. The EDSS in the year before PML onset ranged from 1.0 to 5.0 (mean 2.6; median 2.5) and the Karnofsky scale from 60 to 100 (mean 83; median 80). The mean and median follow-up times were 19.5 and 21.5 months, respectively. There were no fatal outcomes at the time of this analysis.
Clinical presentation and diagnosis of PML
In 12 of the 15 patients, new clinical symptoms like depression, cognitive changes, paresis, ataxia or hemianopsia indicated the development of PML. One patient initially presented with two generalised seizures for the first time in her life.19 In two of the patients, PML suspicious lesions on routine MRI scans were observed without clinical symptoms, indicating very early stages of PML. Optic neuritis or spinal cord symptoms were not noted as early signs of PML.
The median duration from the first symptoms or MRI suspicious lesions to definite diagnosis of PML (by JCV-DNA detection in CSF analysis)20 and removal of natalizumab by PLEX or IA was 30 days (minimum delay 1 day, maximum delay 112 days). In two patients, initially a diagnosis of a new MS relapse was suspected and this delayed proper diagnosis of PML Thus, after typical steroid pulse therapy, these patients unfortunately received another two natalizumab infusions each.
The median CSF viral load at PML diagnosis was 262 copies/ml. In five of the 15 patients, the initial CSF viral load was below 100copies/ml, five had a CSF viral load between 100–2000 copies/ml and three had a high viral load over 2000 copies/ml. In one of the 15 patients, the viral load at PML diagnosis was not quantified, and in another patient with typical clinical symptoms and MRI lesions, JCV-DNA20 remained undetectable in CSF analyses. In 11 patients, the viral load increased during the IRIS phase. CSF became virus-free in eight of the 15 patients after a median time of 4.5 months. A brain biopsy was not needed in any of these cases (table 2).
In all 15 patients, new lesions on brain MRI scans were detectable. PML lesions on initial MRI scans were unilobar in four of the 15 patients. Five of the 11 cases with initially multilobar PML lesions later on spread to bihemispheral affliction. Most of the supratentorial PML lesions were located in the frontal or parietal lobe followed by the occipital, and most rarely, temporal lobe. Only one patient presented with an infratentorial (cerebellar) lesion and two patients had both supratentorial and infratentorial lesions at onset of PML. Gadolinium enhancement in these lesions already at PML diagnosis was observed in four patients (table 3).
While none of the patients had seizures before PML diagnosis, eight of the 15 patients (53%) developed focal, complex-focal or secondary generalised seizures during acute PML phase (see online supplementary table S1). Despite proper antiepileptic treatment (levetiracetam, lacosamide, lamotrigine or topiramate), four of these eight patients were not seizure-free after 1 year post-PML diagnosis. In summary, half of the 15 patients had seizures during acute PML phase, and half of those developed symptomatic focal epilepsy post-PML.
Specific immunorestorative and antiviral treatment
In all 15 patients, PLEX and/or IA were performed to rapidly remove natalizumab and re-establish an intact immune system. Five patients only received PLEX (5–7 sessions), one patient only was treated with IA (5 sessions) and nine patients with PLEX/IA (4–6 sessions). One patient was treated with 9 cycles of PLEX at an external site as an escalating MS relapse therapy, approximately two months before confirmation of PML diagnosis and after that received two more natalizumab infusions. At Bochum, this patient was treated with five cycles of IA to remove natalizumab at the time of PML diagnosis. On clinical grounds, all 15 patients showed initial improvement or stabilisation in the weeks after removal of natalizumab by PLEX/IA.
Supportive therapy with mefloquine (mostly with a loading of 250 mg for 3 days and then typically 250 mg once a week) and mirtazapine (usually a dose of 45 mg per day) were prescribed for all patients. Both mefloquine, an antimalarial agent, and mirtazapine, a 5-hydroxy 2a (5-HT2a)-receptor inhibitor, had shown in vitro inhibitory effects of virus replication.21 ,22 In one patient, the mefloquine had to be stopped because of increasing values of liver enzymes.
Immune reconstitution inflammatory syndrome
Fourteen patients developed IRIS after a mean time of 32 days after natalizumab removal by PLEX/IA. Four patients developed an early-PML-IRIS and 10 patients a late-PML-IRIS. A clinical deterioration indicated the beginning of the IRIS phase in 13 of the 14 patients. In all 14 cases, growing PML lesions with new or progressive gadolinium enhancement on brain MRI scans were found. An increasing CSF viral load was detected in 11 of the 14 patients. During acute IRIS phase, high-dose i.v. corticosteroids (1 g per 3–5 days) were administered, and in two patients, mannitol for the treatment of cerebral oedema was initiated.
In a single patient no IRIS occurred similar to the Dutch patient described in the literature.23
The median follow-up time was 21.5 months from PML diagnosis. We evaluated clinical status at PML diagnosis (pre-IRIS) and post-IRIS in 3–6 monthly intervals. There were no fatal cases at the time of the analysis. Functional disability was measured by Karnofsky score and EDSS. The median EDSS in the year pre-PML was 2.5, 4.5 at PML diagnosis, 6.5 post-IRIS and 5.5 at the latest examination. At PML diagnosis, two patients (13.3%) had mild disability, 11 patients (73.3%) had moderate disability and two patients (13.3%) had severe disability. In IRIS phase, clinical status worsened with the transient need for intensive care unit management in two patients. None of the patients had mild disability, eight (53.3%) had moderate disability and seven (46.6%) had severe disability in IRIS or 1–6 months post PML diagnosis. Patients clinically stabilised after about six months post PML diagnosis. At the latest examination, three patients (20%) had mild disability, nine patients (60%) had moderate disability and three patients (20%) had severe disability.
MS activity and treatment post PML
In nine patients, disease activity (clinical relapse/deterioration due to MS and/or GD enhancement and/or typical T2-lession progression in MRI) reappeared after a mean time of 11 months from PML diagnosis. Clinical relapses or clinical deterioration due to MS reoccurred in four patients after a mean time of 15.5 months. MRI (new contrast enhancement due to MS) activity reappeared in seven patients after a mean time of nine months. In three patients, progression of T2-lesions after a mean time of 15 months was also demonstrated (see online supplementary table S2).
Typically immunmodulatory treatment post-PML was started at the point when CSF was proven virus-free. Yet in one patient, MS activity (new contrast enhancement on brain MRI) reappeared early after 7 weeks post-PML diagnosis. Nine weeks later, this patient was started on interferon ß-1a after the first clinical relapse occurred. At this time CSF viral load still showed 47 copies/ml.
Seven patients received glatiramer acetate, one patient interferon ß-1a, one patient fingolimod and another immunoglobulins as a post-PML MS treatment. One of the patients previously treated with glatiramer acetate had to be escalated to fingolimod. Five patients were stable without continuous immunotherapy (see online supplementary table S3).
Aspects of social life
Two of the 15 patients had to be housed permanently in a nursing home post PML, three patients receive a daily caretaking service and seven patients only received custodial support from their family. Nine of the 15 patients are now early retired and six of these patients require supervision of a legal guardian.
Our study showed that within a median follow-up time of 21.5 months, 15 monocentrically treated natalizumab-associated PML patients revealed a 100% survival rate. Although the global survival rate in natalizumab-associated PML is near 80% (https://www.biogenidec.com), and thus, significantly higher than in HIV-associated PML or in PML of other aetiology,24–26 it came as a surprise that no fatal cases were observed. As indicated by the final Karnofsky score, we indeed had severely afflicted patients in this cohort, and no bias of only low EDSS at onset of PML. One may speculate that the proper timing of antiepileptic treatment and, if needed, provision of intensive care are key elements for improved outcome.
In natalizumab-associated PML, the following aspects were described to be associated with a better outcome: younger age at PML diagnosis, less disability (lower EDSS scores pre-PML), shorter time between symptoms onset and PML diagnosis, more localised MRI lesions and lower JCV load in CSF at PML diagnosis.27 These were the predictors of survival and better outcome found in the first 35 postmarketing PML cases. Natalizumab-associated PML patients revealed mild-to-severe levels of disability. If compared to our study, our cohort had a higher proportion of patients in the range of moderate disability with a Karnofsky score between 50 and 70.
PML may have a ‘freezing effect’ on reoccurrence of MS activity, which may be explained by the autoptic findings reported by Stüve et al.28 Our current data indicate that also in the post-PML setting MS-typical activity on MRI reappears earlier than clinical relapses or clinical deterioration. New contrast enhancement on MRI due to MS was found after a mean time of 9 months post PML, while clinical relapses and T2-lesion progression on MRI were detected after approximately the same time period of 15 to 15.5 months post-PML.
The restart of immunomodulatory therapy post-PML should be considered early when CSF is found free of JCV, at least with the occurrence of new disease activity. The selection of the appropriate post-PML immunomodulatory treatment is an individual decision and depends on clinical conditions and also on the patient's former therapies. Most of our patients were treated with glatiramer acetate post-PML and failed therapy with interferons before escalation of immunotherapy with natalizumab. Of these patients, one later had to be escalated from glatirameracetate to fingolimod and one patient initially received fingolimod as a post PML treatment. At least five patients were stable without continuous immunotherapy. In conclusion, most patients with previously high disease activity are stabilised with baseline therapy or even without immunotherapy after a median follow-up time of almost 2 years post PML-diagnosis. The possible future role of novel oral therapies in the post PML treatment may deserve further consideration.
Eight of the 15 PML patients with seizures in the acute PML phase were not seizure-free over 1 year post PML diagnosis despite appropriate antiepileptic treatment. This is surprising in a disease that predominantly afflicts the white matter. In HIV or other immunosuppressive diseases, IRIS is not known to be as frequent and aggressive as in natalizumab-associated PML. The minor frequency of 18% seizures in a cohort of not natalizumab-associated PML versus 53% in our study may support the assumption of IRIS as a higher risk factor.29 Thus, involvement of cortical or juxtacortical regions during IRIS may explain the relatively high proportion of patients that needed permanent antiepileptic treatment. Therefore, we recommend the continuation of a long-term antiepileptic treatment for PML patients who had seizures in the acute phase of the disease. It is known that the prescribed supportive treatment with mainly mefloquine and mirtazapine decreases the epileptogenic threshold. Yet some of our patients had suffered from seizures already before mefloquine and mirtazapine were started. We recommend that both supportive drugs be continued until the JCV-PCR of CSF yields negative results, although this is not an evidence-based recommendation.
Our current data suggest that survival of natalizumab-associated PML is a result of (I) increased clinical vigilance leading to early diagnosis, and (II) standardised and consequent treatment of PML and IRIS.
We thank Dr Wenning, Offenburg for providing follow-up information on our first common PML patient.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online tables
Contributors SD, RH, AC, IK, KH and RG took care of the patients. CL and OA contributed to MRI analyses and virological assays. Study design was made by KH and RG. The draft of the manuscript was written by SD and RG, and all other co-authors contributed to revision of the manuscript.
Competing interests AC received speaker's and consulting honoraria, scientific grant support from Bayer Healthcare, Biogen-Idec, Merck-Serono, Novartis Pharma, and Teva Pharma. IK reports receiving travel reimbursements and speaker and consulting honoraria from Bayer Healthcare, Biogen-Idec, Merck Serono, and Novartis as well as research support from Bayer Healthcare, Novartis and Biogen-Idec. OA received speaker's honoraria from Biogen Idec. CL received speaker's honoraria from Biogen Idec, Novartis and Merck Serono. KHK. Hellwig reports research support from Biogen Idec, Bayer Healthcare, Merck Serono, Sanofi-Aventis and Novartis Pharma as well as speaker honoraria from Biogen Idec, Bayer Healthcare, Merck-Serono, Sanofi-Aventis and Novartis Pharma. RG has received consultation fees and speakers honoraria from BayerSchering, BiogenIdec, MerckSerono, Novartis, Sanofi-Aventis and TEVA. He also acknowledges grant support from BayerSchering, BiogenIdec, MerckSerono, Sanofi-Aventis and TEVA.
Ethics approval Ruhr University Bochum Ethics Committee no. 4566-13.
Provenance and peer review Not commissioned; externally peer reviewed.